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Management of blood pressure in children with pheochro-
mocytoma and other catecholamine-secreting tumors
(CSTs) is unique and challenging. The authors report a
single-center experience using sequential a-adrenergic
blockade (phenoxybenzamine), increased fluid intake, and
b-blockade for presurgical management of 10 CSTs in
children. In this retrospective review, mean duration for
blood pressure control in preparation for surgery was
4.52.6 weeks. Intraoperative hypertension was noted
transiently (<2 hours) in eight patients (80%) and was
treated with continuous infusion of short-acting antihyper-
tensive agents. Two (20%) patients required vasopressor
medication infusion to manage intraoperative hypotension.
Only two (20%) patients developed postoperative hypo-
tension and required vasopressor medication infusion
for <24 hours. All antihypertensive medications were
discontinued in the immediate (≤4 days) postoperative
period in 80% of patients. In conclusion, a systematic
and multidisciplinary approach utilizing adrenergic block-
ade is effective in treating children with CSTs. J Clin
Hypertens (Greenwich). 2015;17:720–725. ª 2015 Wiley
Periodicals, Inc.
Pheochromocytoma (PH) is a catecholamine-secreting
neuroendocrine tumor that arises from chromaffin cells
in the medulla of the adrenal gland. A total of 5% to
10% originate from the ganglia of the sympathetic or
parasympathetic nervous system (extra adrenal) and are
known as paraganglioma (PG).1–4 Neuroblastoma (NB)
is also a neuroendocrine tumor that originates from the
adrenal gland or primitive neural crest elements in the
sympathetic nervous system.5
Symptoms of these catecholamine-secreting tumors
(CSTs) are secondary to increased catecholamines
(dopamine, norepinephrine, epinephrine, and others)
that are released into the circulation. Most of the PHs
secrete norepinephrine, resulting in hypertension,
tachycardia, cardiac conduction anomalies, headaches,
sweating, flushing, nausea, vomiting, and dizziness.1,2,5–7
Sustained, rather than paroxysmal, hypertension is seen
in 60% to 90% of children with PH/PG.3,6,8 Hyperten-
sion can also be a result of renal artery compression or
tumor effect, particularly in large tumors such as NB.
Intraoperative hypertension associated with catechol-
amine secretion is present in 14.5% of patients with PH/
PG as compared with 3% to 3.5% of patients with
NB.5,9,10
Surgical resection is the mainstay of treatment of
most CSTs.1 Manipulation during the intraoperative
period can lead to massive catecholamine release
resulting in severe hypertensive crisis, cardiac arrhyth-
mias and cerebrovascular accidents. A sudden decrease
in tumor burden and catecholamine effect can cause
post-resection hypotension requiring fluid resuscita-
tion, in turn, leading to pulmonary edema. Goldstein
and colleagues11 reported a reduction in perioperative
complications from 69% to 3% with appropriate
preoperative medical management. Several regimens in
adult patients have used a-adrenergic blockers (phen-
oxybenzamine or doxazosin), calcium channel block-
ers (CCBs) (amlodipine or nifedipine), a tyrosine
hydroxylase inhibitor (a-methyltyrosine), or a com-
bined a- and b-adrenergic blocker (labetalol).3,5,12,13
The First International Symposium on PH also
recommended preoperative management of hyperten-
sion but was not able to establish clear guidelines on
management of blood pressure (BP) in pediatric
patients.14
The aim of this study was to report our single-center
experience with sequential preoperative adrenergic
blockade in children with CSTs. In the current case
series, we also describe the intraoperative course and
postoperative outcomes on a- and b-adrenergic block-
ade regimens.
METHODS
A retrospective review of medical records of children
(6 months–18 years) from 2005–2013 with a diagnosis
of CST undergoing surgical removal was conducted.
CST diagnosis was confirmed by presence of elevated
catecholamines (plasma and/or urine) and tumor on
imaging (computed tomography or magnetic resonance
imaging [MRI]). Cases were identified using The Inter-
national Classification of Diseases, 9th Revision (ICD-
9) coding for PH, PG, and NB with help of a data
analyst in the department of Health Information
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FIGURE. Management of hypertension in children with catecholamine-secreting tumors undergoing surgical removal.
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Management at Children’s Hospital of Michigan.
Excluded from the study were patients with CST with
incomplete medical records or in whom BP was not
treated with adrenergic blockade medication before
surgical removal. Hypertension was defined as BP ≥95
percentile for age, sex, and height on at least three
separate measurements. BP was measured with an
oscillometric device and/or auscultation using an appro-
priately sized cuff. Once a diagnosis of CST was
confirmed and surgical removal scheduled, adrenergic
blockage was initiated and other antihypertensive med-
ications were tapered.
Preoperative preparation was done as per the pro-
posed algorithm (Figure). Phenoxybenzamine (a-adren-
ergic blockade) was started at least 7 to 10 days
preoperatively with a goal to decrease BP to <95
percentile for age, sex, and height. BP was recom-
mended to be monitored twice daily at home in the
seated position. Orthostasis was also monitored at clinic
visits or during hospital admission. Heart rate was
recorded and pulse volume assessed by palpation at each
clinic visit. Patients were advised to increase oral fluid
intake to at least 1.5 times of the daily maintenance fluid
requirement, with an aim to increase pulse volume.
Clinic visits were scheduled at least once a week. At
least 3 days prior to surgery, a b-adrenergic blocker was
administered with a goal to control tachycardia and
decrease heart rate to a normal range for age. All
patients were admitted a day before surgery to ensure
BP control and receive intravenous normal saline prior
to surgery.
Intraoperative hypertension was defined as the need
to use short-acting antihypertensive medication as per
anesthesiologist recommendations for persistent ele-
vated BP readings. Hypotension in the intraoperative
and postoperative periods was treated with crystalloid
and/or colloid (albumin/packed red blood cells) replace-
ment. Vasopressor medications were used in patients
not responding to crystalloid and/or colloids. All
patients were monitored in the Pediatric Intensive Care
Unit after surgery, usually for 24 to 48 hours. BP
medication was tapered according to the pediatric
nephrologists’ recommendation. A multidisciplinary
approach involving the surgeon, anesthesiologist,
hematologist-oncologist, endocrinologist, and pediatric
nephrologist was preferred in overall management.
Data on clinical presentation, diagnostic evaluation,
genetic workup, treatment of hypertension, intraopera-
tive BP control, and postoperative outcomes were
recorded. The study was approved by the institutional
review board of Wayne State University.
RESULTS
Eight hypertensive children with CSTs underwent 10
surgical removal procedures (N=10) during the study
period (Table I). Two children with incomplete records
were excluded from analysis. The median age was
86.5 years (range, 10 months to 18 years) and five
were male. The primary diagnosis was PH in seven
(70%), PG in one (10%), and NB in two (20%)
patients. Bilateral PH was noted in three children and
one patient had two recurrences (each required surgical
intervention). Tachycardia was noted in five (50%),
sweating in five (50%), headache in three (30%)
patients. Sustained hypertension was seen in nine
(90%) and paroxysmal hypertension in one (10%)
patient. Only one (sibling of patient with recurrent PH)
was asymptomatic and was found to be hypertensive on
screening evaluation. Elevated catecholamines (plasma
or urine) were present in all patients. Eight (80%) had
elevated plasma catecholamines: normetanephrine in six
(2–40 9 normal range [N]), norepinephrine in three
(1–20 9 N), dopamine in three (1–6 9 N), and
metanephrine in one (3 9 N). Nine (90%) had elevated
24-hour urine catecholamines: vanillylmandelic acid in
six (3–30 9 N), normetanephrine in five (4–11 9 N),
metanephrines in three (1–6 9 N), homovanillic acid
(HVA) in two (3–4 9 N), and norepinephrine in one.
CST was confirmed by computed tomography scan in
one, MRI in nine, and iodine-131-meta-iodobenzylgua-
nidine scan in nine (90%).
Genetic testing was performed in six of eight children.
Von Hippel-Lindau gene mutation was confirmed in
two patients with PH. One patient was positive for
succinate dehydrogenase subunit B gene mutation. Of
two patients with NB who were screened for N-myc
mutations, one patient was positive. All patients with
PH/PG were prepared for surgery using a-adrenergic
blockade (phenoxybenzamine) followed by b-adrenergic
blockade (atenolol or propranolol or labetalol).
Two children with NB were initially treated with
oral labetalol and preoperative preparation with
phenoxybenzamine was performed once surgery was
scheduled. Dosage and duration of each medication are
shown in Table II. The mean duration to achieve BP
control in preparation for surgery was 4.52.6 weeks.
The intraoperative and postoperative outcomes are
shown in Table III.
DISCUSSION
Our report highlights the importance of a systematic
approach in treating hypertensive children with CST. No
randomized trials or prospective studies are currently
available to compare the different preoperative treatment
regimens for adults or children with CSTs. Mostly,
retrospective studies or case reports in the literature
support the use of an adrenergic blockade regimen.1,10–12
Weingarten and collegues15 report the largest retrospec-
tive series in adults, comparing the perioperative man-
agement algorithm at two different institutions. In
children, Pham and colleagues1 retrospectively reviewed
theirmedical and surgicalmanagement anduseda- andb-
adrenergic blockers for control of hypertension in 76%of
patients. However, intraoperative and postoperative
outcomes on this sequential regimen were not described.
We report our single-center experience of a systematic
approach that can be a useful tool for physicians and
surgeons caring for children with CST.
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The aim of preoperative a-adrenergic blockade is to
prevent the well-known “catecholamine storm” during
induction of anesthesia or at the time of surgical
manipulation of the tumor. The goal is to avoid
hypertensive crisis and/or cardiac arrhythmias by nor-
malizing BP and heart rate before surgery.14–16 Resto-
ration of the contracted blood volume occurs
preoperatively with use of a combination of a-adrener-
gic blockade and increased fluid intake. This
“expanded” intravascular volume in the setting of
aggressive a-blockade reduces the likelihood of post-
resection hypotension.2
Phenoxybenzamine (a noncompetitive a-adrenergic
blocker) was used in all of our patients and has also
been reported to be the preferred drug in adult regimens
because of its longer half-life.2,14,17 Intraoperative
hypertension was transient (<2 hours) in our study
and no patient required continuous infusion of short-
acting antihypertensive medication (nitroprusside, lab-
etalol, or esmolol) in the postoperative period, thus
showing adequate adrenergic blockade. Phenoxybenz-
amine is reported to be advantageous over competitive
or short-acting a1-adrenergic blockers (doxazosin, praz-
osin), which have a risk of being displaced from the
receptor by excessive catecholamine release during
surgery.2,12,14 On the other hand, phenoxybenzamine
is a long-acting agent (half-life of 24 hours)18 as
compared with prazosin (half-life of 3 hours)19 and
has increased risk of postoperative hypotension. In our
series, intraoperative hypotension was treated with
colloid resuscitation in seven (70%) of the cases; one
patient (10%) required vasopressor medication. Two
(20%) patients had postoperative hypotension requiring
vasopressor medication for <24 hours. Thus, phenoxy-
benzamine was a safe option for our patients and did
not lead to persistent postoperative hypotension.
In adults, phenoxybenzamine is usually recommended
to be started 1 to 2 weeks preoperatively.2,3,17,20 In the
large retrospective adult series from the Mayo Clinic,
phenoxybenzamine was used for 1 to 4 weeks prior to
surgery.15,17 Interestingly, the mean duration of phen-
oxybenzamine use was 4.5 weeks in our series, reflect-
TABLE I. Clinical Profile of Children With CSTs (N=10)
Case Age Sex Symptoms
Elevated Catecholamine
Plasma (P) Urine (U) Imaging Diagnosis
1 16 y F Tachycardia
Headache
Normetanephrine (P)
Norepinephrine (P)
Dopamine (P)
Normetanephrine (U)
MRI + MIBG PH (Bilateral)
2 15 y F Headache Normetanephrine (P)
VMA (U)
MRI+MIBG PH
3 12 y M Sweating
Headache
Norepinephrine (P)
Dopamine (P)
VMA (U)
MRI + MIBG PH (Bilateral)
4 18 y M Tachycardia
Sweating
Norepinephrine (P)
Dopamine (P)
Metanephrine (U)
CT + MIBG PG
5 11 months F Tachycardia Normetanephrine (P)
VMA(U)
HVA (U)
MRI + MIBG NB
6 10 months M Tachycardia Normetanephrine (P)
VMA(U)
HVA (U)
MRI + MIBG NB
7 5 y M Asymptomatic Normetanephrine (P)
Normetanephrine (U)
Metanephrine (U)
MRI + MIBG PH
8 3 y M Tachycardia
Sweating
Normetanephrine (U)
Metanephrine (U)
VMA(U)
MRI PH (Left)
5 y Sweating Normetanephrine (U)
Norepinephrine (U)
VMA (U)
MRI + MIBG PH (Right)
5 y Sweating Normetanephrine (P)
Metanephrine (P)
Normetanephrine (U)
MRI + MIBG PH (Recurrence)
Abbreviations: CT, computed tomography; F, female; HVA, homovanillic acid; MIBG, iodine-131-meta-iodobenzylguanidine; M, male; MRI, magnetic
resonance imaging; PH, pheochromocytoma; VMA, vanillyl mandelic acid.
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ing a longer time to achieve target BP (<95 percentile)
and pulse volume. We believe this could be the result of
a lower starting dose of medication, slower dose
increments, and increased sympathetic activity in chil-
dren as compared with adults.
An unusual and unique aspect in the management of
hypertension in CST is increasing water intake.17 The
rationale is to increase the blood volume, reverse
chronic vasoconstriction, and ultimately prevent post-
resection hypotension. In our patients, we clinically
monitored pulse volume to assess the adequacy of
restoration of blood volume. Only two (20%) patients
required vasopressor support in the postoperative
period as compared with 56% adults.15 With a combi-
nation of phenoxybenzamine and increased fluid intake,
we were able to decrease the risk of post-resection
hypotension.
The use of b-adrenergic blockade is recommended to
avoid tachyarrhythmias and achieve better BP control.
However, b-adrenergic blockade should never precede
a-adrenergic blockade since unopposed a-receptor stim-
ulation can cause severe hypertensive crisis.12,14,16 In
our series, the choice of b-adrenergic blockade was as
per physician preference. Four patients received oral
labetalol, which is known to provide a 1:3 a- to b-
adrenergic block ratio, as compared with a 1:7 ratio for
the intravenous infusion.21 Patients were on b-adrener-
gic blockade for a mean duration of approximately
2 weeks before surgery. As noticed with phenoxybenz-
amine, the time to achieve target heart rate and BP was
longer. More importantly, none of our patients experi-
enced cardiac arrhythmias during or after surgery.
In our series, 50% of patients had both intraoperative
hypertension and hypotension. However, none of these
patients had persistent hypertension or hypotension. BP
was stabilized using continuous antihypertensive infu-
sion (50%) of nitroprusside or esmolol and use of
vasopressor medication infusion (10%) for <1 hour
during the intraoperative period. Other medications
such as magnesium sulfate or dexmedetomidine or
nicardipine have also been reported as safe alternatives
in pediatric patients for intraoperative treatment but
were not used in our patients.7,13 The role of anesthe-
siologists is crucial during the intraoperative period
because of rapid fluctuations in BP with induction,
manipulation, and removal of CSTs. As such, a preop-
erative anesthesia consultation is recommended rou-
tinely in these patients.
Different treatment regimens have recommended
CCBs and/or a tyrosine hydroxylase inhibitor
TABLE III. Intraoperative and Postoperative
Treatment of BP in Patients With CSTs (N=10)
Study Variables Frequency
Intra-operative hypertension 3 (30%)
Labetalol infusion, (n) 1
Duration, (hours) 2
Sodium nitroprusside infusion, (n) 1
Duration, (hours) 1.5
Esmolol infusion, (n) 1
Duration, (hours) 1.5
Intra-operative hypotension 2 (20%)
Albumin infusion, (n) 2
PRBC infusion, (n) 2
Vasopressor medication infusion, (n) 1
Duration, (hours) 1
Intra-operative hypertension and hypotension 5 (50%)
Sodium nitroprusside infusion, (n) 3
Duration, (hours) 0.6
Esmolol infusion, (n) 2
Duration, (hours) 1
Albumin infusion, (n) 4
PRBC infusion, (n) 1
Vasopressor medication infusion, (n) 1
Duration, (hours) 0.5
Postoperative hypertension 2 (20%)
Oral anti-hypertensives, (n) 2
Postoperative hypotension 2 (20%)
Crystalloid infusion, (n) 1
Vasopressor medication infusion, (n) 2
Duration <24 hours 2
Discontinuation of all BP medications, (n) 10 (100%)
Immediate post-op period 6
1–4 days 2
>4 days 2
Abbreviations: BP, blood pressure; CSTs, catecholamine-secreting
tumors; PRBC, packed red blood cell.
TABLE II. Preoperative Treatment of BP in Patients
With CSTs (N=10)
Study Variables Frequency
Preoperative a blockade
Phenoxybenzamine, (n) 10
Dose, (mg/kg/d) 0.6
Duration, (weeks) 4.52.6
Preoperative b blockade
Atenolol, (n) 4
Dose, (mg/kg/d) 0.4
Duration, (days) 3414.8
Propranolol, (n) 2
Dose, (mg/kg/d) 0.8
Duration, (days) 30
Labetalol, (n) 4
Dose, (mg/kg/d) 2.3
Duration, (days) 11.59.2
Preoperative volume expansion, (n) 9
Duration, (days) 19.815.2
Duration to achieve BP control in
preparation for surgery, (weeks)
4.52.6
Abbreviations: BP, blood pressure; CSTs, catecholamine-secreting
tumors.
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(metyrosine) in combination with adrenergic block-
ade.14 However, without use of additional drugs we
were able to demonstrate good BP control, as evidenced
by discontinuation of all BP medications in 80% of
patients within 4 days of surgery.
Catecholamine-secreting NB is also reported to cause
severe intraoperative hypertension during induction of
anesthesia.22 In this series, an adrenergic blockade
regimen was successfully utilized in managing two
infants with NB.
STUDY LIMITATIONS
The major limitation of our case series is its retrospec-
tive nature. We acknowledge that we are reporting on a
small number of children with a rare diagnosis of CST.
Our results are based on a single-center experience, and
large prospective studies are required to formulate
treatment guidelines for children with CSTs.
CONCLUSION
A systematic multidisciplinary approach of BP control
with a-blockade, volume expansion, and b-blockade is
necessary in the perioperative period. The preparation
for surgery may take longer (2–4 weeks) in children as
compared with adults. However, goal-directed therapy
to normalize BP, heart rate, and restoration of blood
volume ensures excellent outcomes in children with PH,
PG, and catecholamine-secreting NB.
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